Viewing Study NCT05450692

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 3:35 PM

Ignite Modification Date: 2026-01-04 @ 4:29 PM

Study NCT ID: NCT05450692

Status: ACTIVE_NOT_RECRUITING

Last Update Posted: 2025-11-19

First Post: 2022-07-06

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Sponsor: AstraZeneca

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module